Health care stocks were edging higher pre-bell Tuesday, with the iShares Biotechnology ETF (IBB) and The Health Care Select Sector SPDR Fund (XLV) up 0.1%.
Apellis Pharmaceuticals (APLS) shares were down more than 2% even after the company said Australia's Therapeutic Goods Administration approved Syfovre for the every-other-month treatment of geographic atrophy in adults with age-related macular degeneration resulting in vision loss.
Akero Therapeutics (AKRO) stock was nearly 5% higher after the company said it has started an underwritten public offering of $300 million of shares, with J.P. Morgan, Morgan Stanley and Jefferies as book-running managers.
AstraZeneca (AZN) shares were marginally higher after the company and Daiichi Sankyo said their drug Enhertu has been approved in the US for the treatment of adult patients with certain types of inoperable breast cancer that has progressed on one or more endocrine therapies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。